The Insider Activity Of Oscar Health Inc. (OSCR) Is Worth Monitoring

0
8
BEPC Stock
BEPC Stock

Oscar Health Inc. (NYSE:OSCR) finished Wednesday with a subtraction of -$0.07 to close at $5.37, a downside of -1.29 percent. An average of 2,989,060 shares of common stock have been traded in the last five days. There was a fall of -$0.53 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 2,117,795 shares traded, while the 50-day average volume stands at 1,703,048.

OSCR stock has decreased by -23.07% in the last month. The company shares reached their 1-month lowest point of $5.36 on 09/21/22. With the stock rallying to its 52-week high on 03/30/22, shares of the company touched a low of $3.89 and a high of $18.89 in 52 weeks. It has reached a new high 10 times so far this year and lost -31.59% or -$2.48 in price. In spite of this, the price is down -71.57% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Insider Transactions

16 days have passed since Oscar Health Inc. (OSCR) last reported insider trading activity. Quane Alessandrea C., who is EVP, Chief Insurance Officer, most recently acquired $17,532 shares at $5.53 per share on Sep 06. In this transaction, the insider spent $97,019. Chief Financial Officer, Blackley Richard Scott, disposed of 31,615 shares at a price of $5.53 on Sep 06. The insider now owns more than $174,951 worth of shares. Prior to that, EVP & Chief Legal Officer Bopitiya Ranmali went on to Sale 6,167 shares at $5.85 each on Sep 02. An amount of $36,077 was transacted.

Valuation Metrics

Oscar Health Inc. (OSCR) has a trailing price-to-sales (P/S) ratio at 0.41, the price-to-book (PB) ratio at 0.91, and the price-to-cash flow ratio at 6.04.

Financial Health

Further, the company has a long term debt to equity ratio of 0.24 and a total debt to equity ratio of 0.24 for the quarter ending June 29. Its gross profit as reported stood at -$570.58 million compared to revenue of $1.84 billion.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Oscar Health Inc.’s return on assets was -15.40%.

Earnings Surprise

For the three-month period that ended June 29, Oscar Health Inc. had $297.61 million in total debt. The analyst consensus anticipated Oscar Health Inc.’s latest quarter earnings to come in at -$0.48 per share, but it turned out to be -$0.53, a -10.40% surprise. For the quarter, EBITDA amounted to -$101.38 million. At the end of the quarter ending June 29, Oscar Health Inc.’s stock balance sheet showed total debt was $372.52 million. Shareholders own equity worth $212.2 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Oscar Health Inc. (OSCR) price momentum. RSI 9-day as of the close on 21 September was 29.82%, suggesting the stock is oversold, with historical volatility in this time frame at 64.54%.

As of today, OSCR’s price is $5.65 -8.98% or -$0.53 from its 5-day moving average. OSCR is currently trading -23.29% lower than its 20-day SMA and -30.62% lower than its 100-day SMA. However, the stock’s current price level is +14.26% above the SMA50 and -38.63% below the SMA200.

The stochastic %K and %D were 11.37% and 17.51%, respectively, and the average true range (ATR) was 0.31. With the 14-day stochastic at 0.90% and the average true range at 0.31, the RSI (14) stands at 35.93%. The stock has reached -0.34 on the 9-day MACD Oscillator while the 14-day reading was at -0.32.

Analyst Ratings

BofA Securities downgraded Oscar Health Inc. (NYSE: OSCR) to a an Underperform rating in its most recent analyst report. Previously, the stock was rated as a Neutral.

LEAVE A REPLY

Please enter your comment!
Please enter your name here